Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.47%0700.HK-6.36%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.24%ORCL-0.97%3988.HK-0.44%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.27%0857.HK-1.46%UNH-10.21%1288.HK-1.35%PM-0.85%0005.HK-1.74%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.65%AUDUSD-1.50%EURAUD+0.99%AUDCAD-0.98%AUDCHF-0.97%GBPAUD+0.91%AUDNZD-0.88%NZDJPY-0.79%GBPJPY-0.75%EURJPY-0.69%CADJPY-0.69%CHFJPY-0.69%NZDUSD-0.62%AUDSGD-0.62%GBPUSD-0.58%USDCHF+0.57%AUDDKK-0.55%USDCAD+0.54%EURUSD-0.52%AUDNOK-0.46%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDMXN+0.28%NZDMXN+0.25%USDZAR+0.24%USDTHB+0.23%USDTRY+0.21%USDJPY-0.18%USDILS+0.16%USDNOK+0.16%EURZAR+0.15%CHFNOK+0.14%USDPLN+0.12%USDSEK+0.12%USDCNH-0.12%EURCNH-0.12%NOKJPY-0.11%GBPZAR+0.11%GBPSGD-0.11%NZDCAD-0.10%EURNZD+0.09%CHFSEK+0.09%NZDCHF-0.09%EURHKD-0.08%USDDKK+0.08%EURNOK+0.08%EURSGD-0.07%PLNJPY-0.07%EURGBP+0.07%GBPCAD-0.06%SGDJPY+0.05%EURCZK+0.05%GBPNZD+0.04%EURPLN+0.04%EURCHF+0.04%USDCOP-0.04%EURSEK+0.04%GBPCHF-0.02%CADCHF+0.02%EURCAD+0.01%USDSGD+0.01%CHFSGD-0.01%USDHKD-0.01%NZDSGD0.00%EURDKK0.00%XAGUSD+0.92%GAGUSD+0.92%UKOIL+0.76%XNGUSD-0.74%XAUUSD+0.64%GAUUSD+0.64%USOIL+0.54%W1-0.38%HG1+0.34%XPTUSD+0.31%C1-0.21%COTTON+0.13%BTCUSD-3.18%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.87%ZECUSDT-5.77%XMRUSDT-1.24%DOGEUSD+55.95%LINKUSD-2.90%XLMUSD-3.42%BCHUSDT-3.26%LTCUSD+47.50%UNIUSD-2.23%SUIUSD-2.77%TONUSD+59.18%HBARUSDT-4.64%TAOUSDT-2.68%AAVEUSD-3.06%ONDOUSDT-4.90%ICPUSDT-2.00%DOTUSDT-3.50%WLDUSDT-2.82%ARBUSDT-4.75%ATOMUSDT-2.39%INJUSDT-6.54%STXUSDT-2.03%PYTHUSDT-0.37%TIAUSDT-3.10%FETUSDT-3.79%JUPUSDT+0.63%SEIUSDT-2.00%GRTUSDT-2.69%OPUSDT-2.63%IOTAUSDT-2.40%POLUSDT-1.66%WIFUSDT-2.25%AXSUSDT-2.18%EOSUSDT-3.95%IMXUSDT-2.35%FARTCOINUSDT-5.73%GALAUSDT-1.65%DYDXUSDT-2.05%ORDIUSDT-2.34%NOTUSDT+0.86%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.47%0700.HK-6.36%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.24%ORCL-0.97%3988.HK-0.44%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.27%0857.HK-1.46%UNH-10.21%1288.HK-1.35%PM-0.85%0005.HK-1.74%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.65%AUDUSD-1.50%EURAUD+0.99%AUDCAD-0.98%AUDCHF-0.97%GBPAUD+0.91%AUDNZD-0.88%NZDJPY-0.79%GBPJPY-0.75%EURJPY-0.69%CADJPY-0.69%CHFJPY-0.69%NZDUSD-0.62%AUDSGD-0.62%GBPUSD-0.58%USDCHF+0.57%AUDDKK-0.55%USDCAD+0.54%EURUSD-0.52%AUDNOK-0.46%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDMXN+0.28%NZDMXN+0.25%USDZAR+0.24%USDTHB+0.23%USDTRY+0.21%USDJPY-0.18%USDILS+0.16%USDNOK+0.16%EURZAR+0.15%CHFNOK+0.14%USDPLN+0.12%USDSEK+0.12%USDCNH-0.12%EURCNH-0.12%NOKJPY-0.11%GBPZAR+0.11%GBPSGD-0.11%NZDCAD-0.10%EURNZD+0.09%CHFSEK+0.09%NZDCHF-0.09%EURHKD-0.08%USDDKK+0.08%EURNOK+0.08%EURSGD-0.07%PLNJPY-0.07%EURGBP+0.07%GBPCAD-0.06%SGDJPY+0.05%EURCZK+0.05%GBPNZD+0.04%EURPLN+0.04%EURCHF+0.04%USDCOP-0.04%EURSEK+0.04%GBPCHF-0.02%CADCHF+0.02%EURCAD+0.01%USDSGD+0.01%CHFSGD-0.01%USDHKD-0.01%NZDSGD0.00%EURDKK0.00%XAGUSD+0.92%GAGUSD+0.92%UKOIL+0.76%XNGUSD-0.74%XAUUSD+0.64%GAUUSD+0.64%USOIL+0.54%W1-0.38%HG1+0.34%XPTUSD+0.31%C1-0.21%COTTON+0.13%BTCUSD-3.18%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.87%ZECUSDT-5.77%XMRUSDT-1.24%DOGEUSD+55.95%LINKUSD-2.90%XLMUSD-3.42%BCHUSDT-3.26%LTCUSD+47.50%UNIUSD-2.23%SUIUSD-2.77%TONUSD+59.18%HBARUSDT-4.64%TAOUSDT-2.68%AAVEUSD-3.06%ONDOUSDT-4.90%ICPUSDT-2.00%DOTUSDT-3.50%WLDUSDT-2.82%ARBUSDT-4.75%ATOMUSDT-2.39%INJUSDT-6.54%STXUSDT-2.03%PYTHUSDT-0.37%TIAUSDT-3.10%FETUSDT-3.79%JUPUSDT+0.63%SEIUSDT-2.00%GRTUSDT-2.69%OPUSDT-2.63%IOTAUSDT-2.40%POLUSDT-1.66%WIFUSDT-2.25%AXSUSDT-2.18%EOSUSDT-3.95%IMXUSDT-2.35%FARTCOINUSDT-5.73%GALAUSDT-1.65%DYDXUSDT-2.05%ORDIUSDT-2.34%NOTUSDT+0.86%RONINUSDT-2.92%
VP

Vertex Pharmaceuticals Incorporated (VRTX)

NASDAQ • Healthcare

$536.45
+$2.25 (+0.4%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$532.27
Day Range$531.38 - $542.76
Avg. Volume (3M)1.5M
Market Cap$136B
P/E Ratio34.3
52 Week Range
$412.27$568.67
Next EarningsIn 84 daysFeb 11, 2027

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$3.4B100%
Gross Profitminus cost of goods$2.9B85%
Operating Incomeminus R&D and overhead$712.9M21%
Net Incomeminus taxes and the rest$653.6M19%

In plain terms: out of every $100 in revenue, Vertex Pharmaceuticals Incorporated keeps $19 as net profit.

Fundamentals & Financials

Revenue (TTM)
$12.9B
Net Income (TTM)
$3.9B
EPS (TTM)
$15.66
ROA (TTM)
12.15%
Current Ratio
2.34

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+5.4%Q2 2026$4.47
-0.2%Q3 2026$4.73
-1.2%Q4 2026$4.76
Next

Feb 11

in 84 daysQ1 2027

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Miss -1.2%

Vertex’s third fiscal quarter of 2026 came with revenue rising 11.8% to about $3.4 billion while adjusted EPS of $4.76 trailed the $4.82 estimate (-1.2%) and revenue of $3.441 billion came in line with the $3.419 billion consensus (+0.6%), based on preliminary results reported November 2, 2026. Results were driven by its cystic fibrosis medicines, including TRIKAFTA alongside KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI, sold across the U.S. and international markets. Profitability showed a gross margin of roughly 85% with gross profit of about $2.9 billion, while operating income was roughly $0.7 billion for an operating margin near 21%. Net income fell 39.6% year over year to about $0.7 billion, down from $1.083 billion a year ago, and adjusted EPS slipped 0.8% from $4.80. For the next period, consensus calls for EPS of $4.64 on revenue of $3.514 billion.

View full earnings history

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated develops and markets prescription medicines in biotechnology, centered on cystic fibrosis treatments and a broader genetic-disease pipeline. The NASDAQ-listed company generated $12.1 billion of revenue in FY2025. Its marketed portfolio includes TRIKAFTA for cystic fibrosis patients with at least one F508del mutation, along with KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI.

Name
Vertex Pharmaceuticals Incorporated
CEO
Reshma Kewalramani
Industry
Healthcare
Year Founded
1989
Employees
6,400

Today's Snapshot

AI-generated

VRTX ended the day slightly higher at 536.45, while its sector was weaker. Vertex Pharmaceuticals extended its drug-discovery deal with Genomics Limited, a research partner, worth $220 million.

Trading Volume

Below 10d avg (1.3M)

1.2M

vs S&P 500 Today

Outperforming Market

+0.68%

Updated: November 18, 2026 at 21:27 UTC

Technical Indicators

4 Buy3 Neutral1 Sell
VRTX’s setup leans mildly bullish as the share price remains above longer-term moving averages while short-term averages are clustered close and have recently pressured the market. MACD is positive and longer-term averages support the uptrend, however momentum indicators are soft and ADX signals a lack of strong trend follow-through. Volatility is subdued and the pivot sits near the current price, leaving the market in a consolidation band above the 200-day level. On-balance volume is not confirming strength, so gains are cautious. Technical takeaway: Buy.
All signals
  • EMA (5 indicators)$489.84 - $539.49
    Buy
  • RSI (14)51.64
    Neutral
  • Stochastic %K (14, 3, 3)27.55
    Neutral
  • MACD Level (12, 26)5.10
    Neutral
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.